A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 833 participants.
Also called NCT01849289
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 833 participants
- Sponsor
- Registry
-
NCT01849289
-
- Main results
- A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Canada, China, Romania, South Africa, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01849289. Randomized; no masking; primary purpose treatment. Start 2013-06-02 (actual); primary completion 2014-05-15 (actual). Results posted on 2016-01-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Degludec
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01849289- Content hash
99eed1e9288153e7546c5e74f609cb49584d120adf0c313d4cd5a6674e226fc5